In vitro and in vivo efficacies of teicoplanin-loaded calcium sulfate for treatment of chronic methicillin-resistant Staphylococcus aureus osteomyelitis.

Antimicrobial Agents and Chemotherapy
Wei-Tao JiaJian-Qiang Wang

Abstract

The in vitro and in vivo therapeutic efficacies of teicoplanin-loaded calcium sulfate (TCS; 10% [wt] teicoplanin) were investigated in a rabbit model of chronic methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis. The in vitro elution characteristics of teicoplanin from TCS pellets were realized by carrying out an evaluation of the release kinetics, recovery rate, and antibacterial activity of the released teicoplanin. Chronic osteomyelitis was induced by inoculating 10(7) CFU of a MRSA strain into the tibial cavity of rabbits. After 3 weeks, the animals were treated by debridement followed by implantation of TCS pellets in group 1, calcium sulfate (CS) pellets alone in group 2, and intravenous (i.v.) teicoplanin (6 mg/kg of body weight every 12 h for three doses and then every 24 h up to 4 weeks) in group 3. Animals in group 4 were left untreated. After 6 weeks, the efficacy of the osteomyelitis treatment was evaluated by hematological, radiological, microbiological, and histological examinations. In vitro elution studies showed sustained release of teicoplanin at a therapeutic level over a time period of 3 weeks. The released teicoplanin maintained its antibacterial activity. In vivo, the best therapeutic effect ...Continue Reading

References

Oct 1, 1991·Journal of Clinical Microbiology·K MurakamiS Watanabe
Mar 1, 1990·The Journal of Antimicrobial Chemotherapy·P MaroneM Cruciani
May 1, 1997·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·M S SmeltzerR P Evans
Dec 29, 2000·Journal of Chemotherapy·M J Wood
Nov 2, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·H M Ziglam, R G Finch
Jan 26, 2002·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·J. LeFrock, A. Ristuccia
Aug 10, 2002·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Carl L NelsonKeith M Olsen
Aug 15, 2002·International Journal of Pharmaceutics·I YeniceA Hincal
Oct 29, 2002·Journal of Orthopaedic Surgery·Steven Gitelis, Gregory T Brebach
Jun 30, 2004·American Journal of Surgery·Brad Parsons, Elton Strauss
Jul 28, 2004·Lancet·Daniel P Lew, Francis A Waldvogel
Nov 24, 2004·Clinical Orthopaedics and Related Research·Alex C McLaren
Aug 2, 2005·Clinical Orthopaedics and Related Research·Arlen D Hanssen
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Patrice Courvalin
Jan 6, 2006·Journal of Long-term Effects of Medical Implants·Mark V ThomasMohanad Al-Sabbagh
Aug 15, 2006·Clinical Orthopaedics and Related Research·Andras HeijinkArlen D Hanssen
Mar 30, 2007·International Orthopaedics·M ColangeliS Giannini
Jun 19, 2007·Clinical Orthopaedics and Related Research·Valentin AntociJavad Parvizi
May 28, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·George Sakoulas, Robert C Moellering

❮ Previous
Next ❯

Citations

Jan 8, 2013·Expert Opinion on Drug Delivery·Otto S KluinDaniëlle Neut
Mar 16, 2019·Journal of Medical Microbiology·Marta BottagisioArianna B Lovati
May 15, 2018·The Open Orthopaedics Journal·Kuzma Jerzy, Hombhanje Francis
Apr 23, 2013·Clinical Orthopaedics and Related Research·J Keaton SmithWarren O Haggard

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.